You are here: Home: Meet The Professors Vol. 2 2004: Case 2: Select publications
 |
| Select publications |
 |
1Boccardo F. Presentation. San Antonio Breast Cancer Symposium, 2003. 2Boccardo F et al. Anastrozole appears to be superior to tamoxifen in women already receiving adjuvant tamoxifen treatment. Breast Cancer Res Treat 2003;82(Suppl1); Abstract 3 .
Cauley JA et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year resultsfromtheMOREtrial. Multiple outcomes of raloxifene evaluation. Breast Cancer ResTreat 2001;65(2):125-34. Abstract
Coombes RC et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350(11):1081-92. Abstract
Gnant M et al. Changes in bone mineral density caused by anastrozole or tamoxifen in combination with goserelin (± zoledronate) as adjuvant treatment for hormone receptor-positive premenopausal breast cancer: results of a randomized multicenter trial. Breast Cancer Res Treat 2002; Abstract 12.
Goss PE et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl JMed 2003;349(19):1793-802. Abstract
Howell A et al. Effect of anastrozole on bone mineral density: 2-year results of the 'arimidex' (anastrozole), tamoxifen, alone or in combination (ATAC) trial. Breast Cancer Res Treat 2003; . Abstract 129
Locker GY et al. The time course of bone fractures observed in the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial. Proc ASCO 2003; Abstract 98 .
O'Regan RM et al. Effects of raloxifene after tamoxifen on breast and endometrial tumor growth in athymic mice. J Natl CancerInst 2002;94(4):274-83. Abstract
|
